Discovery of the inhibitor of DNA binding 1 as a novel marker for radioresistance in pancreatic cancer using genome-wide RNA-seq
作者机构:Department of Radiation OncologyUniversity of Arkansas for Medical SciencesLittle RockAR 72205USA Department of Biochemistry and Molecular BiologyUniversity of Arkansas for Medical SciencesLittle RockAR 72205USA
出 版 物:《Cancer Drug Resistance》 (癌症耐药(英文))
年 卷 期:2022年第5卷第4期
页 面:926-938页
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金:Center for Microbial Pathogenesis and Host Inflammatory Responses, (P20GM103625) NIH National Institute of General Medical Sciences Centers of Biomedical Research Excellence National Institutes of Health, NIH, (KL2 TR003108) National Institutes of Health, NIH National Center for Advancing Translational Sciences, NCATS
主 题:Pancreatic cancer radiation resistance ID1 RNA-seq
摘 要:Purpose/Objective(s): Discovery of genetic drivers of radioresistance is critical for developing novel therapeuticstrategies to combine with radiotherapy of radioresistant PDAC. In this study, we used genome-wide RNA-seq toidentify genes upregulated in generated radioresistant PDAC cell lines and discovered the Inhibitor of DNA Binding1 (ID1) gene as a potential regulator of radioresistance in ***/Methods: Radioresistant clones of the PDAC cell lines MIA PaCa-2 and PANC-1 were generated bydelivering daily ionizing irradiation (IR) (2 Gy/day) in vitro over two weeks (total 20 Gy) followed by standardclonogenic assays following one week from the end of IR. The generated RR and parental cell lines were submittedfor RNA-seq analysis to identify differentially expressed genes. The Limma R package was used to calculatedifferential expression among genes. Log2 fold change values were calculated for each sample compared to thecontrol. Genes with an absolute fold change 1 were considered significant. RNA sequencing expression data fromthe Cancer Genome Atlas (TCGA) database was analyzed through the online databases GEPIA, cBioPortal, and theHuman Protein ***: Following exposure to two weeks of 2 Gy daily IR in vitro, the two PDAC cell lines showed significantlygreater clonogenic cell survival than their parental cell lines, indicating enhanced RR in these cells. RNA-seqanalysis comparing parental and RR cell lines found upregulated seven genes (TNS4, ZDHHC8P1, APLNR, AQP3,SPP1, ID1, ID2) and seven genes downregulated (PTX3, ITGB2, EPS8L1, ALDH1L2, KCNT2, ARHGAP9, IFI16) in bothRR cell lines. Western blotting confirmed increased expression of the ID1 protein in the RR cell lines compared totheir parental cell lines. We found that ID1 mRNA was significantly higher in PDAC tumors compared to matchednormal and high ID1 expression correlated with significantly worse disease-free survival (DFS) in PDAC patients(HR = 2.2, log rank P = 0.009). ID1 mRNA express